To investigate the clinical efficacy of thalidomide combined with CHOP in the treatment of peripheral T-cell lymphoma.

A total of 72 patients with peripheral T-cell lymphoma treated in Liaocheng People’s Hospital from January 2017 to January 2019 were selected, and were divided into observation group (36 cases) and control group (36 cases) according to the random number table. CHOP was used in the control group, while thalidomide was used in the observation group. Three weeks was one course of treatment, and both groups received 8 consecutive courses of treatment. The clinical curative effect and levels of arginase 1 (Arg-1), vascular endothelial growth factor (VEGF), induce nitric oxide synthase (iNOS) compared before and after the two groups and the adverse reactions during the treatment of (gastrointestinal reaction, liver damage, bone marrow suppression, neurotoxicity, hair loss, skin rash) were compared between the two groups.

After treatment, the total effective rate of observation group (86.11%) was higher than that of the control group (63.89%), the difference was statistically significant (P<0.05). After treatment, levels of Arg-1, VEGF and iNOS were (12.38±2.50) ng/ml, (20.11±10.02) pg/ml and (14.96±3.72) U/ml respectively in the observation group, lower than (14.29±2.40) ng/ml, (32.72±10.43) pg/ml and (16.77±3.80) U/ml in the control group , with significant differences (P<0.05). During the treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Thalidomide combined with CHOP has significant clinical effect in the treatment of peripheral T-cell lymphoma. It can effectively reduce Arg-1, VEGF and iNOS levels, without increasing the incidence of adverse reactions.

Lymphoma, T-cell, peripheral; CHOP plan; Thalidomide